BioRestorative Therapies, Inc. (BRTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 250K 500K 750K FY11: 0 FY12: 15.6K FY13: 1.7K FY14: 416K FY15: 628.9K FY16: 36.4K FY17: 81K FY18: 111K FY19: 130K FY20: 77K FY21: 46K FY22: 119.8K FY23: 145.8K FY24: 401K FY25: 359.7K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 150K 300K 450K FY11: 0 FY12: 14.3K FY13: 1.5K FY14: 202.2K FY15: 367.4K FY16: 36.3K FY17: 81K FY23: 145.8K FY24: 372.9K FY25: 335.9K FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY23 FY24 FY25

Operating Income Annual

-27M -18M -9M 0 9M 18M 27M FY10: -2.1M FY11: -3.6M FY12: -5.6M FY13: -4.8M FY14: -4.9M FY15: -7.2M FY16: -7.8M FY17: -8.4M FY18: -7.6M FY19: -8.4M FY20: -2.8M FY21: -26.3M FY22: -19M FY23: -15.2M FY24: -11.6M FY25: -15.6M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-60M -40M -20M 0 20M 40M 60M FY09: -1.2M FY10: -2.3M FY11: -4.1M FY12: -6.5M FY13: -5.8M FY14: -5.6M FY15: -7.9M FY16: -8.6M FY17: -9.4M FY18: -12.5M FY19: -14.6M FY20: -11.3M FY21: -44.3M FY22: -13.2M FY23: -10.4M FY24: -9M FY25: -14.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 10K 20K 30K FY24: 28.1K FY25: 23.8K FY24 FY25

Operating Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY10: -729.2K FY11: -2.8M FY12: -3.2M FY13: -2.7M FY14: -3.2M FY15: -3.1M FY16: -5M FY17: -3.9M FY18: -5.1M FY19: -6.9M FY20: -2M FY21: -3.3M FY22: -5.9M FY23: -6.4M FY24: -8.2M FY25: -10.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY10: -774.6K FY11: -2.8M FY12: -3.2M FY13: -2.7M FY14: -3.4M FY15: -3.5M FY16: -5.2M FY17: -3.9M FY18: -5.1M FY19: -7M FY21: -3.4M FY22: -6.2M FY23: -6.6M FY24: -8.3M FY25: -10.9M FY10 FY12 FY14 FY16 FY18 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 3.5M 7M 10.5M FY21: 1.2M FY22: 3.6M FY23: 4.2M FY24: 7.8M FY25: 9M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '10: 0.00 Q1 '11: 0.00 Q2 '11: 0.00 Q3 '11: 0.00 Q4 '11: 0.00 Q1 '12: -0.13 Q2 '12: -0.25 Q3 '12: -0.36 Q4 '12: -0.48 Q1 '13: -0.45 Q2 '13: -0.41 Q3 '13: -0.38 Q4 '13: -0.36 Q1 '14: -0.34 Q2 '14: -1.43 Q3 '14: -2.16 Q4 '14: -2.93 Q1 '15: -3.85 Q2 '15: -3.32 Q3 '15: -3.08 Q4 '15: -3.30 Q1 '16: -2.99 Q2 '16: -2.91 Q3 '16: -2.77 Q4 '16: -2.11 Q1 '17: -1.98 Q2 '17: -1.93 Q3 '17: -1.87 Q4 '17: -1.76 Q1 '18: -1.59 Q2 '18: -1.61 Q3 '18: -1.63 Q4 '18: -1.63 Q1 '19: -1.52 Q2 '19: -1.23 Q3 '19: -1.07 Q4 '19: -0.66 Q1 '20: -0.39 Q2 '20: -0.15 Q3 '20: -2.02 Q4 '20: -14.74 Q1 '22: -14.31 Q2 '22: -15.59 Q3 '22: -11.88 Q4 '22: -5.61 Q1 '23: -5.21 Q2 '23: -5.40 Q3 '23: -3.73 Q4 '23: -2.47 Q1 '24: -0.87 Q2 '24: 0.10 Q3 '24: -0.42 Q4 '24: -1.16 Q1 '25: -1.47 Q2 '25: -1.27 Q3 '25: -1.47 Q4 '25: -1.59 Q1 '26: -1.07 Q1 '11 Q1 '13 Q1 '15 Q1 '17 Q1 '19 Q1 '22 Q1 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.